Medicinal Polypharmacology-a Scientific Glossary of Terminology and Concepts

Overview

Journal Front Pharmacol

Date 2024 Aug 2

PMID 39092220

Authors

Sven Marcel Stefan

Muhammad Rafehi

Affiliations

Soon will be listed here.

Abstract

Medicinal polypharmacology is one answer to the complex reality of multifactorial human diseases that are often unresponsive to single-targeted treatment. It is an admittance that intrinsic feedback mechanisms, crosstalk, and disease networks necessitate drugs with broad modes-of-action and multitarget affinities. Medicinal polypharmacology grew to be an independent research field within the last two decades and stretches from basic drug development to clinical research. It has developed its own terminology embedded in general terms of pharmaceutical drug discovery and development at the intersection of medicinal chemistry, chemical biology, and clinical pharmacology. A clear and precise language of critical terms and a thorough understanding of underlying concepts is imperative; however, no comprehensive work exists to this date that could support researchers in this and adjacent research fields. In order to explore novel options, establish interdisciplinary collaborations, and generate high-quality research outputs, the present work provides a first-in-field glossary to clarify the numerous terms that have originated from various individual disciplines.

Citing Articles

Computer-aided pattern scoring (C@PS): a novel cheminformatic workflow to predict ligands with rare modes-of-action.

Stefan S, Stefan K, Namasivayam V J Cheminform. 2024; 16(1):108.

PMID: 39313842 PMC: 11421111. DOI: 10.1186/s13321-024-00901-5.

References

Hopkins A, Mason J, Overington J . Can we rationally design promiscuous drugs?. Curr Opin Struct Biol. 2006; 16(1):127-36. DOI: 10.1016/j.sbi.2006.01.013. View

Stefan S . Multi-target ABC transporter modulators: what next and where to go?. Future Med Chem. 2019; 11(18):2353-2358. DOI: 10.4155/fmc-2019-0185. View

Koch O . Use of secondary structure element information in drug design: polypharmacology and conserved motifs in protein-ligand binding and protein-protein interfaces. Future Med Chem. 2011; 3(6):699-708. DOI: 10.4155/fmc.11.26. View

Korcsmaros T, Szalay M, Bode C, Kovacs I, Csermely P . How to design multi-target drugs. Expert Opin Drug Discov. 2013; 2(6):799-808. DOI: 10.1517/17460441.2.6.799. View

Orengo C, Jones D, Thornton J . Protein superfamilies and domain superfolds. Nature. 1994; 372(6507):631-4. DOI: 10.1038/372631a0. View

Vulpetti A, Kalliokoski T, Milletti F . Chemogenomics in drug discovery: computational methods based on the comparison of binding sites. Future Med Chem. 2012; 4(15):1971-9. DOI: 10.4155/fmc.12.147. View

Morphy R, Kay C, Rankovic Z . From magic bullets to designed multiple ligands. Drug Discov Today. 2004; 9(15):641-51. DOI: 10.1016/S1359-6446(04)03163-0. View

Duarte C, Barreiro E, Fraga C . Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007; 7(11):1108-19. DOI: 10.2174/138955707782331722. View

Bray M, Singh S, Han H, Davis C, Borgeson B, Hartland C . Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes. Nat Protoc. 2016; 11(9):1757-74. PMC: 5223290. DOI: 10.1038/nprot.2016.105. View

10.

Stork C, Kirchmair J . PAIN(S) relievers for medicinal chemists: how computational methods can assist in hit evaluation. Future Med Chem. 2018; 10(13):1533-1535. DOI: 10.4155/fmc-2018-0116. View

11.

Morphy R, Rankovic Z . Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005; 48(21):6523-43. DOI: 10.1021/jm058225d. View

12.

Li D, Li Y, Jiang X, Liu W, Zhao Q . Evodiamine: A Privileged Structure with Broad-ranging Biological Activities. Mini Rev Med Chem. 2022; 22(21):2680-2701. DOI: 10.2174/1389557522666220404090835. View

13.

Zhan P, Liu X . Designed multiple ligands: an emerging anti-HIV drug discovery paradigm. Curr Pharm Des. 2009; 15(16):1893-917. DOI: 10.2174/138161209788453266. View

14.

Stefan S, Rafehi M . Medicinal polypharmacology: Exploration and exploitation of the polypharmacolome in modern drug development. Drug Dev Res. 2023; 85(1):e22125. DOI: 10.1002/ddr.22125. View

15.

Hu Y, Bajorath J . Polypharmacology directed compound data mining: identification of promiscuous chemotypes with different activity profiles and comparison to approved drugs. J Chem Inf Model. 2010; 50(12):2112-8. DOI: 10.1021/ci1003637. View

16.

Morphy R, Rankovic Z . Fragments, network biology and designing multiple ligands. Drug Discov Today. 2007; 12(3-4):156-60. DOI: 10.1016/j.drudis.2006.12.006. View

17.

Morphy R, Rankovic Z . Designing multiple ligands - medicinal chemistry strategies and challenges. Curr Pharm Des. 2009; 15(6):587-600. DOI: 10.2174/138161209787315594. View

18.

Zimmermann G, Lehar J, Keith C . Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007; 12(1-2):34-42. DOI: 10.1016/j.drudis.2006.11.008. View

19.

Puri S, Stefan K, Khan S, Pahnke J, Stefan S, Juvale K . Indole Derivatives as New Structural Class of Potent and Antiproliferative Inhibitors of Monocarboxylate Transporter 1 (MCT1; SLC16A1). J Med Chem. 2022; 66(1):657-676. PMC: 9841531. DOI: 10.1021/acs.jmedchem.2c01612. View

20.

McKie S . Polypharmacology: in silico methods of ligand design and development. Future Med Chem. 2016; 8(5):579-602. DOI: 10.4155/fmc-2015-0006. View